Livforsakringsbolaget Skandia Omsesidigt Acquires 11,200 Shares of Halozyme Therapeutics, Inc. $HALO

Livforsakringsbolaget Skandia Omsesidigt raised its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 10.7% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 116,100 shares of the biopharmaceutical company’s stock after acquiring an additional 11,200 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Halozyme Therapeutics were worth $7,504,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Empowered Funds LLC bought a new stake in shares of Halozyme Therapeutics in the 1st quarter valued at $755,000. Acadian Asset Management LLC bought a new position in Halozyme Therapeutics during the first quarter worth $195,000. Hsbc Holdings PLC boosted its stake in Halozyme Therapeutics by 117.1% during the second quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock worth $522,000 after acquiring an additional 5,448 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 174 shares during the period. Finally, Baird Financial Group Inc. grew its holdings in Halozyme Therapeutics by 6.2% in the second quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock worth $577,000 after purchasing an additional 650 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares in the company, valued at approximately $1,084,650. The trade was a 33.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $71.75, for a total value of $1,435,000.00. Following the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $55,088,215. This represents a 2.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 74,102 shares of company stock worth $5,205,798. Insiders own 2.50% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on HALO shares. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, June 16th. UBS Group reaffirmed a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, Morgan Stanley dropped their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.60.

Halozyme Therapeutics Stock Down 1.4%

Halozyme Therapeutics stock opened at $75.05 on Wednesday. The firm has a market capitalization of $8.90 billion, a price-to-earnings ratio of 27.00, a price-to-earnings-growth ratio of 0.32 and a beta of 0.84. The firm’s fifty day moving average price is $71.32 and its two-hundred day moving average price is $70.03. Halozyme Therapeutics, Inc. has a 1-year low of $55.64 and a 1-year high of $82.26. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. During the same period in the previous year, the firm posted $1.11 earnings per share. The firm’s revenue for the quarter was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities research analysts predict that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.